SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 ...
Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage ...
SHANGHAI and HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, ...
Arbutus Biopharma Corporation announced plans to initiate a Phase 2b clinical trial in the first half of 2025 after reporting promising results from its Phase 2a trial, where a significant functional ...
GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program ...
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies SOMERVILLE, Mass., Dec. 1, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback